The project “Cardiovascular ischemic injury regeneration using Wharton Jelly as unlimited therapeutic stem cells source” (CIRCULATE) proposes a new approach to the treatment of selected cardiovascular diseases based on the use of allogeneic transplantation of Wharton’s Jelly derived Mesenchymal Stem Cells (WJMSC).
The main goals of the project will be accomplished through:
- establishment of WJMSC repository
- characterization of the WJMSC using cellular and molecular methods
- evaluation of the clinical WJMSCs potential in selected cardiovascular diseases using novel MRI (Magnetic Resonance Imaging) methodology
- assessment of seeding properties and regenerative potential of WJMSC using in vivo models.
Implementation of the Circulate project will generate novel knowledge about the WJMSC biology and new MRI technology to monitor regeneration process in different diseases.
It will allow development of new treatment strategies for cardiovascular diseases using cell replacement therapy. The project will have a strong impact on developing the field of regenerative medicine, which is still in its infancy. Moreover, the project will allow in future introduction of allogeneic stem cells, in the form of the “out of shelf” product, capable of regeneration of various organs and tissues.
The CIRCULATE project has received founding under the Programme called STRATEGMED II (Agreement No. Strategmed2/265761/10/NCBR/2015).
STRATEGMED „Prevention and treatment of diseases of civilization” is a strategic research and development program prepared and founded by the National Center for Research and Development and approved by the Minister of Science and Higher Education.
The CIRCULATE project has received a grant of 32 404 665PLN.
The key objective of the STRATEGMED is to achieve a significant progress in the treatment of civilization diseases and regenerative medicine based on results achieved from research and development activities conducted in the following areas:
- Cardiology and cardiacsurgery
- Neurology and senses
The Programme aims to stimulate the innovation and competitiveness of Polish economy, particularly in biotechnology, biomedical engineering areas, by means of projects oriented on development and implementation of new methods used in the areas of: prevention, diagnosis, medical treatment and rehabilitation.
Moreover, STRATEGMED will strengthen Poland’s international competitive position in following areas: research and development activities in the scientific fields related to STRATEGMED, involvement of dynamic international teams of young researches and finally, transfer of know-how and new technologies to the Polish economy.